Welcome to our dedicated page for Lipocine SEC filings (Ticker: LPCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lipocine Inc. (LPCN) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, including current reports, quarterly and annual reports, and exhibits filed with the U.S. Securities and Exchange Commission. According to recent Form 8‑K filings, Lipocine uses these reports to announce clinical and corporate developments such as Phase 3 trial progress, data presentations, and financial results.
Current reports on Form 8‑K have documented events including enrollment and interim safety milestones in the Phase 3 clinical trial of LPCN 1154 for postpartum depression, presentation of LPCN 2101 data at the American Epilepsy Society annual meeting, and presentation of LPCN 2401 clinical data at ObesityWeek. Other 8‑K filings reference updated corporate presentations and the company’s participation in investor conferences, as well as press releases announcing quarterly financial and operational results.
Lipocine’s periodic reports on Forms 10‑Q and 10‑K, referenced in its press releases, provide more detailed information on revenues from TLANDO licensing and royalties, research and development expenses related to candidates such as LPCN 1154 and LPCN 2401, general and administrative costs, and cash and investment balances. These filings also include risk factor discussions and forward‑looking statements that describe uncertainties around clinical trials, regulatory approvals, partnering, and commercialization.
On Stock Titan, investors can review Lipocine’s SEC filings in one place and use AI‑powered summaries to interpret dense disclosures. Real‑time updates from EDGAR allow users to see new 8‑K, 10‑Q, and 10‑K filings as they appear, while Form 4 and related insider transaction reports can be accessed to monitor trading by Lipocine’s officers and directors. AI tools help highlight key points from lengthy documents, such as clinical program updates, revenue drivers from TLANDO agreements, and changes in operating expenses, giving a clearer view of how Lipocine’s oral drug development strategy is reflected in its official regulatory record.
On 9 July 2025 Lipocine Inc. (NASDAQ: LPCN) filed a Form 8-K under Item 8.01 – Other Events. The sole disclosure is that the company hosted a virtual key-opinion-leader (KOL) event focused on LPCN 1154 (BRLIZIO™) as a potential treatment for postpartum depression. A webcast link and slide deck are available on the corporate website, and the materials have been furnished as Exhibit 99.1.
Under Item 9.01 the filing lists Exhibit 104 (Inline XBRL cover page). No financial metrics, clinical trial results, or transactional details accompany the notice. The document is signed by President & CEO Mahesh V. Patel.
This 8-K signals continued development and external engagement around LPCN 1154 but provides no new quantitative data likely to affect near-term valuation.
Lipocine (NASDAQ:LPCN) filed an 8-K announcing that the first patient has been dosed in its Phase 3 clinical trial of LPCN 1154 for postpartum depression. The disclosure, furnished under Item 8.01 with the press release attached as Exhibit 99.1, marks the transition of LPCN 1154 into late-stage development—an essential step toward potential NDA submission and commercialization. No changes to financial guidance, funding, or corporate strategy were reported, and Items 2.02, 5.02 or other sections were not included. While the filing contains no revenue figures, the milestone may accelerate future catalysts such as data read-outs, regulatory meetings and partnership discussions that could materially influence valuation.